3D Gens welcomed a delegation from the Bioeconomy Corporation to its additive manufacturing facility for a focused engagement around bioprinting technology and medical applications. The visit provided an opportunity to showcase 3D Gens' homegrown bioprinting systems and its broader portfolio of medical products, and to open conversations about how the two organisations might collaborate for better healthcare outcomes.
Bioprinting and the Bioeconomy
The Bioeconomy Corporation plays a central role in Malaysia's strategy to develop a knowledge-intensive bioeconomy — one where biological resources and biotechnology drive economic growth and social benefit. Additive manufacturing, and bioprinting in particular, sits at an important intersection of this agenda: it enables the production of complex biological structures, tissue scaffolds, drug delivery devices, and medical implants with a level of customisation and precision that traditional manufacturing cannot match.
For the Bioeconomy Corporation, understanding the current state of bioprinting in Malaysia — including what 3D Gens has achieved with its GENSx170 system — is relevant to mapping where investment and collaboration can have the most impact.
What 3D Gens Demonstrated
The visiting team was shown 3D Gens' bioprinting systems in operation, along with examples of medical products produced using additive manufacturing — including patient-specific implants and anatomical models. The demonstrations illustrated both the technological capability and the clinical relevance of the work 3D Gens is doing.
Next Steps
Discussions around potential collaboration are ongoing. The alignment between the Bioeconomy Corporation's mandate and 3D Gens' capabilities in medical AM makes this a natural partnership to develop further — with healthcare outcomes as the shared measure of success.